Lack of value of repeat stool testing for Clostridium difficile toxin

Area of Science:

• Infectious Diseases
• Gastroenterology
• Clinical Microbiology

Background:

• Clostridium difficile infection (CDI) is a significant cause of antibiotic-associated diarrhea and pseudomembranous colitis in hospitalized patients.
• Antibiotics and chemotherapy agents can disrupt gut flora, increasing CDI risk.
• C. difficile produces toxins A and B, key virulence factors in disease pathogenesis.

Purpose of the Study:

• To evaluate the diagnostic utility of repeat stool testing for Clostridium difficile toxins A and B via enzyme immunoassay (EIA) in hospitalized patients presenting with nosocomial diarrhea while on antibiotic therapy.

Main Methods:

• Retrospective analysis of inpatient cases with nosocomial diarrhea and antibiotic exposure.
• Stool samples were tested for C. difficile toxins A and B using EIA.
• Comparison of initial and repeat EIA results to assess diagnostic yield.

Main Results:

• Initial EIA for C. difficile toxins A and B demonstrated variable sensitivity and specificity.
• Repeat EIA testing in patients with initial negative results did not significantly improve the overall diagnostic accuracy for C. difficile-associated diarrhea.
• The gold standard C. difficile cell culture cytotoxin assay exhibits higher sensitivity and specificity compared to EIA.

Conclusions:

• Repeat stool testing for C. difficile toxins A and B by EIA in inpatients with nosocomial diarrhea on antibiotics offers limited additional diagnostic value.
• Clinicians should be aware of the limitations of EIA and consider alternative diagnostic strategies or confirmatory testing when C. difficile infection is suspected despite negative EIA results.